SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Livzon Pharmaceutical unit gets NMPA approval for leuprorelin acetate microspheres injection

Reuters reports the unit received an NMPA drug supplementary application approval notice for leuprorelin acetate microspheres for injection 11.25mg (3-month formulation).

000513.SZ1513.HK

Sept. 29 — Livzon Pharmaceutical Group Inc said a unit received a drug supplementary application approval notice from China’s NMPA for leuprorelin acetate microspheres for injection 11.25mg, a 3-month formulation. Further company coverage: 000513.SZ.

Related stories